<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400487</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-039</org_study_id>
    <nct_id>NCT04400487</nct_id>
  </id_info>
  <brief_title>Actigraphy Improvement With Voxelotor (ActIVe) Study</brief_title>
  <acronym>ActIVe</acronym>
  <official_title>A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the effect of voxelotor on daily physical activity and sleep&#xD;
      quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD)&#xD;
      and chronic moderate anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive Voxelotor as treatment. There will be approximately 13 sites in&#xD;
      the US.&#xD;
&#xD;
      Participant safety and tolerability will be monitored during the study using standard&#xD;
      measures, including physical examinations, vital signs (including temperature, blood&#xD;
      pressure, pulse rate, respiratory rate and peripheral oxygen saturation [SpO2]), clinical&#xD;
      laboratory tests, and adverse event (AE) monitoring.&#xD;
&#xD;
      Screening Period (up to 4 weeks in duration): During this period, participants will sign the&#xD;
      informed consent form (ICF), after which they will complete the screening assessments as&#xD;
      detailed in the Schedule of Assessments (SOA).&#xD;
&#xD;
      Run-in Period (2 weeks in duration): During this period, participants will enter a 2-week&#xD;
      run-in period (Day -14 to Day -1) during which baseline actigraphy measures of physical&#xD;
      activity and sleep quality, overnight pulse oximetry assessments of oxygen saturation, and&#xD;
      Patient-Reported Outcome (PRO) assessments will be collected before initiating treatment with&#xD;
      voxelotor.&#xD;
&#xD;
      Treatment Period (24 weeks in duration): After completion of the 14-day Run-in Period,&#xD;
      participants will enter the open label treatment period and receive voxelotor 1500 mg once&#xD;
      daily for 24 weeks. Repeat actigraphy assessments of physical activity and sleep quality, and&#xD;
      overnight pulse oximetry will be performed during the treatment period (Weeks 10 to 12 and&#xD;
      Weeks 22 to 24). PRO and Clinical Global Impression (CGI) assessments will be completed at&#xD;
      scheduled study visits. The open-label treatment period is considered the continuous 24 weeks&#xD;
      of voxelotor treatment from date of first dose (Day 1).&#xD;
&#xD;
      Follow-up Period (4 weeks in duration): Immediately following the 24-week treatment period,&#xD;
      participants will enter a 4-week Follow-up Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total daily physical activity</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Change in total daily physical activity (expressed in counts per minute)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total nocturnal sleep time</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Change in total nocturnal sleep time (TST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in wake time after sleep onset</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Change in wake time after sleep onset (WASO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sleep efficiency</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Change in sleep efficiency (SE) measured as total sleep time/time in bed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mean nocturnal hemoglobin oxygen saturation percentage</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Change in mean overnight SpO2 percentage as measured by pulse oximetry SpO2 percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with a &gt;1 g/dL increase in Hb</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Proportion of participants with a &gt;1 g/dL increase in Hb</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in median number of overnight SpO2 dips &gt; 3% per hour</measure>
    <time_frame>Baseline, Week 10-12, Week 22-24</time_frame>
    <description>Change in median number of overnight SpO2 dips &gt; 3% per hour as measured by pulse oximetry SpO2 percent</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Sickle Cell Anemia</condition>
  <arm_group>
    <arm_group_label>Voxelotor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive voxelotor at 1500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxelotor</intervention_name>
    <description>500 mg Tablet, Oral, With or Without Food</description>
    <arm_group_label>Voxelotor</arm_group_label>
    <other_name>GBT440</other_name>
    <other_name>Oxbryta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants with SCA (sickle hemoglobin with two sickle cell genes&#xD;
             [HbSS] or sickle hemoglobin (S) and one beta thalassemia gene [HbS β0] thal genotype)&#xD;
&#xD;
          2. Between 12 to 55 years of age (inclusive)&#xD;
&#xD;
          3. Screening Hb level ≤8.0 g/dL&#xD;
&#xD;
          4. Treatment with hydroxyurea (HU) therapy on study is permitted if the participant has&#xD;
             been on a stable dose for at least 90 days before enrollment with no dose&#xD;
             modifications planned or anticipated by the Investigator&#xD;
&#xD;
          5. Treatment with glutamine is permitted&#xD;
&#xD;
          6. Treatment with erythropoiesis-stimulating agents (ESAs) is permitted if the&#xD;
             participant has been on a stable dose for at least 12 weeks before enrollment with no&#xD;
             dose modifications planned or anticipated by the Investigator&#xD;
&#xD;
          7. Female participants of child-bearing potential must use highly effective methods of&#xD;
             contraception to 30 days after the last dose of study drug. Male participants must use&#xD;
             barrier methods of contraception to 30 days after the last dose of study drug&#xD;
&#xD;
          8. Females of child-bearing potential are required to have a negative pregnancy test&#xD;
             before the administration of study drug&#xD;
&#xD;
          9. Written informed consent and/or parental/guardian consent and participant assent per&#xD;
             Institutional Review Board (IRB) policy and requirements, consistent with ICH&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Red blood cell (RBC transfusion within 3 months before initiation of study drug&#xD;
&#xD;
          2. Planned initiation of regularly scheduled RBC transfusion therapy (also termed&#xD;
             chronic, prophylactic, or preventive transfusion) during the study&#xD;
&#xD;
          3. Hospitalization for vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within&#xD;
             30 days prior to informed consent/assent.&#xD;
&#xD;
          4. More than 10 VOCs requiring hospitalization, emergency department or clinic visit&#xD;
             within the past 12 months&#xD;
&#xD;
          5. Planned elective surgery within the next 6 months&#xD;
&#xD;
          6. Physical inactivity attributable to clinically significant musculoskeletal,&#xD;
             cardiovascular, or respiratory comorbidities&#xD;
&#xD;
          7. Anemia due to bone marrow failure (eg, myelodysplasia)&#xD;
&#xD;
          8. Absolute reticulocyte count (ARC) &lt; 100 x10^9/L&#xD;
&#xD;
          9. Screening alanine aminotransferase (ALT) &gt; 4× upper limit of normal (ULN)&#xD;
&#xD;
         10. Severe renal dysfunction (estimated glomerular filtration rate [GFR] &lt; 30 mL/min/1.73&#xD;
             m2 by Schwartz formula) or is on chronic dialysis&#xD;
&#xD;
         11. Known active hepatitis A, B or C or known to be human immunodeficiency virus&#xD;
             (HIV)-positive.&#xD;
&#xD;
         12. Females who are breast-feeding or pregnant&#xD;
&#xD;
         13. Major surgery within 8 weeks before enrollment. Participants must have completely&#xD;
             recovered from any previous surgery before enrollment&#xD;
&#xD;
         14. History of hematopoietic stem cell transplant or gene therapy&#xD;
&#xD;
         15. Received an investigational drug within 30 days or 5-half-lives, whichever is longer,&#xD;
             prior to consent, or is currently participating in another trial of an investigational&#xD;
             or marketed drug (or medical device)&#xD;
&#xD;
         16. Use of concomitant medications (eg, crizanlizumab) that confound the ability to&#xD;
             interpret data from the study&#xD;
&#xD;
         17. Medical, psychological, or behavioral condition that, in the opinion of the&#xD;
             Investigator, would confound or interfere with evaluation of safety and/or efficacy of&#xD;
             the study drug, prevent compliance with the study protocol; preclude informed consent;&#xD;
             or, render the participant unable/unlikely to comply with the study procedures&#xD;
&#xD;
         18. Use of herbal medications (e.g., St. John's Wort), sensitive cytochrome P450 (CYP) 3A4&#xD;
             substrates with a narrow therapeutic index, strong CYP3A4 inhibitors, fluconazole, or&#xD;
             moderate or strong CYP3A4 inducers&#xD;
&#xD;
         19. Symptomatic coronavirus disease of 2019 (COVID-19) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Moehring, Pharm D</last_name>
    <phone>650-351-4738</phone>
    <email>bmoehring@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Martinisi</last_name>
    <phone>1-650-452-7918</phone>
    <email>jmartinisi@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UConn Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sasia-Marie Jones</last_name>
      <phone>860-679-7879</phone>
      <email>sajones@uchc.edu</email>
    </contact>
    <investigator>
      <last_name>Biree Andemariam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Ladd</last_name>
      <phone>404-785-2572</phone>
      <email>stacy.ladd@choa.org</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Ciccolo</last_name>
      <phone>617-724-4102</phone>
      <email>NCICCOLO@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sharl Azar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Williams</last_name>
      <phone>313-745-4276</phone>
      <email>cwilliam8@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Glaros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10476</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer De Los Santos</last_name>
      <phone>718-741-2050</phone>
      <email>jennifer.delossantos@einsteinmed.org</email>
    </contact>
    <investigator>
      <last_name>Deepa Manwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitali Pradhan</last_name>
      <phone>201-423-3585</phone>
      <email>Mitali.Pradhan@Mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Glassberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Department of Pediatrics</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Muller</last_name>
      <phone>919-684-6180</phone>
      <email>lindsey.muller@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Nirmish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Landes</last_name>
      <phone>614-366-8445</phone>
      <email>kristina.landes@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Payal C Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Connor</last_name>
      <phone>412-802-8498</phone>
      <email>connora2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Laura DeCastro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Harry</last_name>
      <phone>713-500-6648</phone>
      <email>Cara.L.Harry@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Modupe Idowu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Health</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thokozeni Lipato</last_name>
      <phone>804-828-9357</phone>
      <email>thokozeni.lipato@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Thokozeni Lipato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

